Jay Lee, MD, University of California, Los Angeles, CA, gives an overview of upcoming practice-changing trials in the field of non-small cell lung cancer (NSCLC), including the Phase III CheckMate 816 trial (NCT02998528) of neoadjuvant nivolumab, an anti-PD-L1 monoclonal antibody, plus ipilimumab or chemotherapy in early stage, resectable NSCLC. A promising event-free survival and pathologic complete response (pCR) were observed in patients receiving nivolumab. Dr Lee additionally highlights the Phase III KEYNOTE-091 trial (NCT02504372) of adjuvant pembrolizumab in stage IB/II-IIIA NSCLC, which will potentially build on the results of the IMpower010 trial (NCT02486718). This interview took place at the 2022 Targeted Therapies of Lung Cancer Meeting (TTLC 2022).

свернуть